# Clarithromycin Treatment to Prevent Sepsis Progression in CAP (REACT)

> **NCT06294600** · PHASE3 · RECRUITING · sponsor: **Hellenic Institute for the Study of Sepsis** · enrollment: 330 (estimated)

## Conditions studied

- Community-acquired Pneumonia

## Interventions

- **DRUG:** Clarithromycin 500mg
- **DRUG:** Tablets

## Key facts

- **NCT ID:** NCT06294600
- **Lead sponsor:** Hellenic Institute for the Study of Sepsis
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-02-12
- **Primary completion:** 2026-04-05
- **Final completion:** 2026-07-30
- **Target enrollment:** 330 (ESTIMATED)
- **Last updated:** 2025-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06294600

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06294600, "Clarithromycin Treatment to Prevent Sepsis Progression in CAP (REACT)". Retrieved via AI Analytics 2026-08-24 from https://api.ai-analytics.org/clinical/NCT06294600. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*